Senna Tablets

Assessment should consider the cause of constipation and the contributions of other medicines, diet, activity and fluid intake. Some patients need a planned bowel-care regimen, while new or persistent symptoms may require investigation. The clinician or pharmacist should consider whether a stimulant laxative is appropriate and how response will be reviewed. Severe unexplained pain, bleeding or a swollen abdomen requires assessment before taking a laxative. Repeated unsupervised use can obscure an underlying problem.

Abdominal cramps and diarrhoea are common adverse effects. Excessive or prolonged use can disturb fluids and electrolytes, including potassium. Suspected obstruction, severe dehydration or significant unexplained abdominal symptoms requires medical review. Electrolyte changes can affect people taking certain cardiac medicines or diuretics. Severe weakness, fainting or palpitations needs assessment. The actual labeled sennoside content, age eligibility and administration instructions should be verified instead of comparing crude botanical-extract amounts.

These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.

The catalogue describes a tablet presentation. The exact salt, coating, score line and release characteristics need confirmation from the authorized product information. A milligram strength identifies ingredient quantity; it does not establish whether a tablet may be split, crushed or exchanged for another formulation.

Keep the product in its labeled packaging so the batch, expiry and instructions remain identifiable. Follow the actual label for storage conditions and disposal. Do not use a damaged or unidentified tablet, and keep all medicines securely out of children’s reach.

Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.

A clinician or pharmacist should assess the cause of symptoms, alarm features and interacting medicines before selecting treatment. Persistent or recurrent symptoms require review. The exact authorized label determines formulation-specific administration and local restrictions.